|
|
|||||||||||||
|
|
||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Paper |
1 Institute of Pharmacology and Toxicology, University of Zurich, Switzerland, Switzerland
* To whom correspondence should be addressed. E-mail: andre.vonbueren{at}kispi.unizh.ch.
Accepted 5 May 2007
| Abstract |
|---|
Background: Salbutamol has been shown to mediate anabolic effects after intravenous administration. However, the underlying mechanism responsible for anabolic actions of salbutamol remains unknown.
Objective: To investigate potential mechanism by which salbutamol mediates anabolic effects in vitro.
Methods: Potential androgenic activity of salbutamol was investigated in vitro by the A-Screen assay that measures androgen-dependent inhibition of proliferation of the androgen receptor (AR)-positive human mammary carcinoma cell line, MCF7-AR1.
Results: The assay was validated with three known androgens (methyltrienolone (R1881), 5-
dihydrotestosterone (DHT) and danazol). IC50 values of R1881, DHT and danazol, 4.41 x 10-11, 4.44 x 10-11 and 1.08 x 10-8 M, were in the range known from earlier studies. Our results indicate that salbutamol exhibits androgenic activity, with an IC50 value of 8.93 x 10-6 M. Anti-estrogenic or cytotoxic effects which might have interfered with the assay, were excluded by additional experiments on wildtype MCF7 and MCF7-AR1 cells, respectively.
Conclusion: These data indicate that salbutamol exerts anabolic effects through androgen receptor agonistic activity in vitro.
Key Words: albuterol, androgen, androgen receptor, asthma, beta-2 agonist
Relevant Article
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | REGISTER |